GO
Loading...

Valeant Pharmaceuticals International Inc

More

  • Jan 29- Bankrupt drugmaker Dendreon Corp has reached a stalking-horse deal with Canada's Valeant Pharmaceuticals International Inc to sell the worldwide rights to its cancer vaccine, Provenge, and certain assets for $296 million. The deal is subject to higher and better bids and extended the bid deadline to Feb. 10 for interested parties to participate in an...

  • Valeant to buy worldwide rights to Dendreon's Provenge Thursday, 29 Jan 2015 | 9:29 PM ET

    Jan 29- Valeant Pharmaceuticals International Inc said it would buy the worldwide rights of Dendreon Corp's Provenge drug and certain other assets through a "stalking horse" deal for $296 million. Seattle- based Dendreon filed for bankruptcy protection in November, after sales of its cancer vaccine fell short of expectations and left the company deep in debt.

  • Pershing Square names Stephen Fraidin as vice chairman Tuesday, 20 Jan 2015 | 11:21 AM ET

    NEW YORK— Hedge fund Pershing Square Capital Management on Tuesday named Stephen Fraidin as its vice chairman, touting his experience in mergers and acquisitions. Pershing Square, which is run by activist investor Bill Ackman, said Fraidin was an adviser on its unsuccessful bid for Botox maker Allergan and has been a key adviser on other important investments.

  • Midday movers: Apple, Ford Motor, Yahoo & more Thursday, 8 Jan 2015 | 1:28 PM ET

    Some of Thursday's midday movers:

  • Rate hikes would be positive for these stocks: Pro Wednesday, 7 Jan 2015 | 5:06 PM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Rate hikes mean an improving economy and an improving economy will help these stocks, fund manager David Nicholas told CNBC.

  • Bill Ackman: Herbalife is like Bernie Madoff Wednesday, 7 Jan 2015 | 11:26 AM ET
    Bill Ackman appears on CNBC's "Squawk Box" in the debut of its new set in Manhattan.

    Bill Ackman renewed his attack on Herbalife during a CNBC interview Wednesday, likening the nutrition and weight management company to Bernie Madoff.

  • Dec 18- Hedge fund Paulson& Co has taken a stake in specialty pharmaceuticals company Salix Pharmaceuticals Ltd as the company recovers from inventory issues and the departure of its chief financial officer, according to people familiar with the matter. The fund has recently taken a number of large positions in healthcare companies, including Shire PLC, where...

  • It spent $5.7 billion for the rights to some injectable wrinkle treatments of Valeant Pharmaceuticals and for L'Oreal's share of a dermatology joint venture the two operated. Nestle is also spending about $350 million on dermatology research and development this year, said Humberto Antunes, chief executive of Nestle Skin Care. The first of the new research...

  • Midday movers: Abercrombie & Fitch, Conn's & more Tuesday, 9 Dec 2014 | 12:37 PM ET

    Some of Tuesday's midday movers:

  • Valeant to drop deal-making to cut debt, lift stock Tuesday, 9 Dec 2014 | 9:00 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Valeant Pharmaceuticals is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt and boost its stock price.

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • Early Movers: UTX, LULU, AEO, VZ, AMZN & more Tuesday, 9 Dec 2014 | 7:48 AM ET

    Some of the names on the move ahead of the open.

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • Midday movers: Intel, Toyota, Petrobras & more Friday, 21 Nov 2014 | 12:25 PM ET
    Trader on the floor of the New York Stock Exchange.

    Take a look at some of Friday's midday movers:

  • Valeant slashes stake in Allergan after losing bid Thursday, 20 Nov 2014 | 7:14 PM ET

    Nov 20- Valeant Pharmaceuticals International Inc said it cut its stake in Allergan Inc to 0.1 percent from 9.7 percent, three days after Actavis Plc trumped its offer for the Botox maker. Pershing Square Capital Management informed Valeant that PS Fund 1 sold all of its 2.2 million shares in Allergan allocated to Valeant USA, Valeant said in a regulatory filing.

  • Nov 20- Canada's Valeant Pharmaceuticals International Inc said it may buy back up to $2 billion worth of securities, replacing a previous $1.5 billion program under which it bought back no securities. The announcement comes a few days after acquisition-hungry Valeant's $54 billion offer to buy Botox maker Allergan Inc was trumped by Actavis Plc's $66...

  • Midday Movers: Dillard's, GoPro, Apple & more Thursday, 20 Nov 2014 | 12:29 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Take a look at some of Thursday's midday movers:

  • Ackman has the luck of a loser, to the tune of $2.2B Tuesday, 18 Nov 2014 | 7:02 AM ET
    Bill Ackman

    Heads he wins. Tails he wins. That was the situation Bill Ackman found himself in — or perhaps more accurately, orchestrated — on Monday.

  • Mega-mergers are popular again on Wall Street Tuesday, 18 Nov 2014 | 6:47 AM ET

    Deals worth $100 billion on Monday put the Street on pace for a year rivaling the dot-com bubble era and the private equity surge just before the financial crisis.

  • Hedge funds ditch Apple for AbbVie and Alibaba Tuesday, 18 Nov 2014 | 5:29 AM ET
    A couple look at an Apple Inc. iPhone 6 at an Apple store in the China Central Mall in Beijing, China, on Tuesday, Nov. 11, 2014.

    Hedge funds flocked to Apple ahead of launch of the iPhone 6, but the company is now the most sold position among some of world's largest funds.